Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2010

01-06-2010 | Meeting Report

The second cellular therapy of cancer symposium, 27–29 March 2009, Milan, Italy

Authors: John S. Bridgeman, David E. Gilham, Robert E. Hawkins, Eleanor J. Cheadle

Published in: Cancer Immunology, Immunotherapy | Issue 6/2010

Login to get access

Excerpt

The second Cellular Therapy of Cancer Symposium, held in Milan, Italy last March, buoyed by the success of the Inaugural 2006 meeting in Manchester, UK, again brought together leading figures in cellular therapy research. The increase in delegate numbers registered in Milan surely reflected the rising interest in the field fuelled by recent high profile publications demonstrating the success of adoptive cell therapy in cancer patients. …
Metadata
Title
The second cellular therapy of cancer symposium, 27–29 March 2009, Milan, Italy
Authors
John S. Bridgeman
David E. Gilham
Robert E. Hawkins
Eleanor J. Cheadle
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0748-x

Other articles of this Issue 6/2010

Cancer Immunology, Immunotherapy 6/2010 Go to the issue

ACKNOWLEDGEMENT TO REVIEWERS

Acknowledgement

Original Article

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting

Original Article

Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma

Original Article

Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity

Meeting Report

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008

Original Article

Circulating tumour-derived microvesicles in plasma of gastric cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits